TELO
NASDAQTelomir Pharmaceuticals Inc.
Price$1.05-0.18 (-14.63%)
2026-07-152026-10-15
News · 26 weeks32-60%
2026-04-192026-10-11
Mix1690d
- SEC Filings8(50%)
- Other5(31%)
- Insider3(19%)
Latest news
25 items- SECSEC Form 8-K filed by Telomir Pharmaceuticals Inc.8-K - Telomir Pharmaceuticals, Inc. (0001971532) (Filer)
- PRTelomir Pharmaceuticals Secures $5.6 Million Financing as Billionaire Entrepreneur John Paul DeJoria Increases Investment in the CompanyMIAMI, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Telomir Pharmaceuticals, Inc. (NASDAQ:TELO), a clinical-stage biotechnology company developing small-molecule therapeutics targeting epigenetic and metabolic drivers of cancer, today announced an approximately $5.6 million private investment in public equity (PIPE) financing through the issuance of common stock, without any accompanying investor warrants or convertible securities. The financing includes an additional $1.0 million investment from billionaire entrepreneur and existing significant shareholder John Paul DeJoria, co-founder of John Paul Mitchell Systems and Patrón Spirits. Other existing shareholders and new investors also participated
- SECTelomir Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Telomir Pharmaceuticals, Inc. (0001971532) (Filer)
- PRTelomir Announces Peer-Reviewed Publication Showing Telomir-Zn Restores Visual Function and Retinal Structure in a Model of Age-Related Macular Degeneration (AMD)MIAMI, Sept. 17, 2026 (GLOBE NEWSWIRE) -- Telomir Pharmaceuticals, Inc. (NASDAQ:TELO), a clinical-stage biotechnology company developing small-molecule therapeutics targeting epigenetic and metabolic drivers of cancer, today announced the peer-reviewed publication of new preclinical research showing that Telomir-Zn significantly improved visual function, restored retinal structure, and reduced mitochondrial oxidative stress in a model of age-related macular degeneration (AMD). The findings extend the scientific understanding of Telomir-Zn beyond oncology, providing new evidence that modulation of intracellular metal homeostasis may influence disease-associated pathways across substantiall
- SECTelomir Pharmaceuticals Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - Telomir Pharmaceuticals, Inc. (0001971532) (Filer)
- SECTelomir Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Telomir Pharmaceuticals, Inc. (0001971532) (Filer)
- PRTelomir Announces Research with The Ohio State University Demonstrating In-Vitro Anti-Cancer Activity in Human and Canine Osteosarcoma ModelsMIAMI, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Telomir Pharmaceuticals, Inc. (NASDAQ:TELO), a clinical-stage biotechnology company developing small-molecule therapeutics targeting epigenetic and metabolic drivers of cancer, announced new research findings from The Ohio State University College of Veterinary Medicine demonstrating that Telomir-Zn produces inhibition of cell growth across human and canine osteosarcoma models. The findings establish a translational foundation for evaluating the compound in a naturally occurring disease setting while the company's TNBC program simultaneously advances toward site initiation and Phase 1/2 patient enrollment. Research FindingsConducted under the dire
- SECSEC Form DEFA14A filed by Telomir Pharmaceuticals Inc.DEFA14A - Telomir Pharmaceuticals, Inc. (0001971532) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Telomir Pharmaceuticals Inc.SCHEDULE 13G/A - Telomir Pharmaceuticals, Inc. (0001971532) (Subject)
- SECSEC Form 10-Q filed by Telomir Pharmaceuticals Inc.10-Q - Telomir Pharmaceuticals, Inc. (0001971532) (Filer)
- SECTelomir Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Telomir Pharmaceuticals, Inc. (0001971532) (Filer)
- PRTelomir Announces Peer-Reviewed Publication Demonstrating Telomir-Zn Suppresses Tumor Growth in TNBC and Prostate Cancer ModelsMIAMI, Aug. 10, 2026 (GLOBE NEWSWIRE) -- Telomir Pharmaceuticals, Inc. (NASDAQ:TELO), a clinical-stage biotechnology company developing small-molecule therapeutics targeting epigenetic and metabolic drivers of cancer, today announced the peer-reviewed publication of preclinical data of Telomir-Zn suppressing tumor growth in prostate and triple-negative breast cancer (TNBC) models through selective modulation of intracellular iron and copper. The manuscript, titled "Telomir-Zn Modulates Intracellular Iron and Copper to Inhibit JmjC Histone Demethylases and Suppress Tumor Growth in Prostate and Triple-Negative Breast Cancer," has been published in the Journal of Oncology Research and Therap
- SECSEC Form DEF 14A filed by Telomir Pharmaceuticals Inc.DEF 14A - Telomir Pharmaceuticals, Inc. (0001971532) (Filer)
- INSIDERSEC Form 4 filed by Director Macpherson Edward Clouston4 - Telomir Pharmaceuticals, Inc. (0001971532) (Issuer)
- INSIDERSEC Form 4 filed by Director Del Giudice Matthew Paul4 - Telomir Pharmaceuticals, Inc. (0001971532) (Issuer)
- INSIDERSEC Form 4 filed by Director Whalen Matthew Pratt4 - Telomir Pharmaceuticals, Inc. (0001971532) (Issuer)
- SECTelomir Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Telomir Pharmaceuticals, Inc. (0001971532) (Filer)
- NEWSTelomir Pharmaceuticals Announces Peer-Reviewed Publication in Biomedicine & Pharmacotherapy Demonstrating Restoration of Insulin Sensitivity with Telomir-Zn in a Preclinical Type 2 Diabetes ModelInsulin Resistance Was Normalized Following 14 Days of Treatment, Supporting Restoration of Glucose Metabolism and Insulin Sensitivity and Further Validating Telomir-Zn's Metal-Homeostasis Mechanism Across Multiple Disease Models. MIAMI, FL / ACCESS Newswire / June 15, 2026 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) ("Telomir" or the "Company"), a clinical-stage biotechnology company developing small-molecule therapeutics targeting epigenetic and metabolic drivers of cancer and age-related disease, today announced the peer-reviewed publication of preclinical data demonstrating restoration of insulin sensitivity and significant improvement in glucose homeostasis with Telomir-Zn in a diet-i
- INSIDERSEC Form 3 filed by new insider Mushak Andriy3 - Telomir Pharmaceuticals, Inc. (0001971532) (Issuer)
- SECTelomir Pharmaceuticals Inc. filed SEC Form 8-K: Financial Statements and Exhibits8-K - Telomir Pharmaceuticals, Inc. (0001971532) (Filer)
- INSIDERSEC Form 4 filed by CEO and Chairman Aminov Erez4 - Telomir Pharmaceuticals, Inc. (0001971532) (Issuer)
- INSIDERSEC Form 4 filed by Director Whalen Matthew Pratt4 - Telomir Pharmaceuticals, Inc. (0001971532) (Issuer)
- INSIDERSEC Form 4 filed by Director Macpherson Edward Clouston4 - Telomir Pharmaceuticals, Inc. (0001971532) (Issuer)
- INSIDERSEC Form 4 filed by Director Del Giudice Matthew Paul4 - Telomir Pharmaceuticals, Inc. (0001971532) (Issuer)
- SECTelomir Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Telomir Pharmaceuticals, Inc. (0001971532) (Filer)
TELO FAQ
6 questionsWhere does TELO stock trade?
Telomir Pharmaceuticals Inc. (TELO) is listed on NASDAQ.What sector and industry is TELO in?
Telomir Pharmaceuticals Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Telomir Pharmaceuticals Inc. go public?
Telomir Pharmaceuticals Inc. (TELO) completed its IPO in 2024.What are analysts saying about TELO?
Telomir Pharmaceuticals Inc. has had 1 recent analyst action on file. The most recent action was from Rodman & Renshaw: Buy with a $1500.00 price target on 2025-02-21. Recent price targets cluster around $1500.00.What companies are similar to TELO?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare TELO side-by-side with any of them on Quantisnow.How can I track TELO on Quantisnow?
Quantisnow aggregates Telomir Pharmaceuticals Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow TELO to receive live email and push alerts on every new disclosure.